"Replicative RNA Vectors for ErbB-2 Polynucleotide Vaccination."

According to an abstract submitted by the authors to the 4th International Conference on Gene Therapy of Cancer, held November 9-11, 1995, in San Diego, California, "The tumor associated antigen erbB-2 (encoded by HER-2/neu) is a transmembrane growth factor receptor which is overexpressed in 20-30% of human breast carcinomas and is associated with tumor aggressiveness, increased resistance to chemotherapy, and decreased overall and disease-free survival. As such, erbB-2 has been the target of immunotherapeutic approaches to breast cancer. One powerful strategy to generate specific antitumor immunity is polynucleotide vaccination (PNV), a rapidly developing technology of eliciting immune...

Want to see the full article?

• Purchase this article for only $3.00